<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-26-12-2025-shutterstock_2340757177-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-26-12-2025-shutterstock_2340757177-430x241.jpg"/>
                                    
                                    <figcaption>RP-3467 is a potent small molecule inhibitor of Polθ, a synthetic lethality target linked to BRCA mutations and other genomic alterations. Credit: PeopleImages/Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467.</p>



<p>The transaction involves a total consideration of up to $30m to Repare and directly influences the company’s cash status and upcoming shareholder arrangements.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>NPVM: Repare Therapeutics Inc's RP-6306 </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>NPVM: Replimune Ltd's Vusolimogene Oderparepvec </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>According to the terms, Gilead will pay Repare $25m upfront, subject to customary holdbacks and adjustments, and up to an additional $5m upon completion of certain technology transfer activities.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>On 14 November 2025, Repare announced a definitive arrangement agreement with XenoTherapeutics and Xeno Acquisition. Under this agreement, Xeno agreed to purchase all of Repare’s issued and outstanding common shares.</p>



<p>The amount of cash each shareholder will receive per share will be based on Repare’s closing cash balance, after subtracting transaction-related expenses and outstanding liabilities.</p>



<p>The upfront payment from the Polθ ATPase inhibitor acquisition has increased Repare’s cash reserves, thereby raising the estimate for shareholder payments.</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>Based on the revised cash balance, Repare estimates shareholders will receive about $2.20 per common share upon closing the arrangement transaction.</p>



<p>Repare Therapeutics president, CEO and chief financial officer Steve Forte said: “We are pleased to announce this transaction which combines Gilead’s leading expertise in oncology research and development with RP-3467, a potential best-in-class Polθ ATPase inhibitor. This marks the third and most significant portfolio transaction for Repare this year.”</p><div id="slot-two"></div>



<p>RP-3467 is a potent small molecule inhibitor of Polθ, a synthetic lethality target linked to breast cancer gene (BRCA) mutations and other genomic alterations.</p>



<p>In May 2025, Repare entered an out-licensing agreement with Canadian biotechnology firm DCx Biotherapeutics for discovery platforms and intellectual property (IP).</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>



                   
               <div>
                 <h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
                 <p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
<br/>
<br/>
<strong>Excellence in Action</strong>
<br/>Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.</p>
Discover the Impact

             </div>

RPTX

GILD

<p>Gilead Sciences has agreed to acquire Repare Therapeutics' Polθ ATPase inhibitor, RP-3467, for up to $30 million. The deal includes a $25 million upfront payment and up to $5 million upon technology transfer completion. This acquisition boosts Repare's cash reserves, impacting shareholder payments, estimated at $2.20 per share. Repare's CEO, Steve Forte, highlights the transaction as a significant portfolio move, combining Gilead's oncology expertise with RP-3467's potential in targeting BRCA mutations.</p>

Gilead Sciences to acquire Repare’s RP-3467